205 362

Cited 1 times in

Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study

Authors
 Jimyung Park  ;  Seng Chan You  ;  Jaehyeong Cho  ;  Chan Hyuk Park  ;  Woon Geon Shin  ;  Rae Woong Park  ;  Seung In Seo 
Citation
 BMC PHARMACOLOGY & TOXICOLOGY, Vol.23(1) : 9, 2022-01 
Journal Title
BMC PHARMACOLOGY & TOXICOLOGY
Issue Date
2022-01
MeSH
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19 / complications ; COVID-19 / epidemiology* ; COVID-19 / therapy ; Female ; Histamine H2 Antagonists / therapeutic use* ; Hospitalization / statistics & numerical data ; Humans ; Incidence ; Male ; Middle Aged ; Proton Pump Inhibitors / therapeutic use* ; Republic of Korea / epidemiology ; Retrospective Studies ; Risk Factors ; SARS-CoV-2* ; Treatment Outcome ; Young Adult
Keywords
Acid suppressants ; Epidemiology ; Pharmacovigilance ; Retrospective studies
Abstract
Background: This study aimed to evaluate incidence risk and adverse clinical outcomes in COVID-19 disease among short-term users of acid-suppressants in South Korea.

Methods: This retrospective cohort study, conducted using a nationwide claims database for South Korea, used data from patients with COVID-19 tested between January 1 and May 15, 2020. Patients aged over 18 years and prescribed proton pump inhibitors (PPI) or histamine-2 receptor antagonist (H2RA) for more than 7 days were identified. Primary outcome was COVID-19 while secondary outcomes were all-cause mortality, hospitalization with respiratory disease, or intensive respiratory intervention. Large-scale propensity scores were used to match patients, while the Cox proportional hazard model was utilized to evaluate any association between exposure and outcome(s). The risk estimates were calibrated by using 123 negative control outcomes.

Results: We identified 26,166 PPI users and 62,117 H2RA users. After propensity score matching, compared to H2RA use, PPI use was not significantly associated with lower risk of COVID-19 (calibrated hazard ratio [HR], 0.81 [95% confidence interval (CI), 0.30-2.19]); moreover, PPI use was not associated with adverse clinical outcomes in COVID-19, namely, hospitalization with respiratory disease (calibrated HR, 0.88 [95% CI, 0.72-1.08]), intensive respiratory interventions (calibrated HR, 0.92 [95% CI, 0.46-1.82]), except for all-cause mortality (calibrated HR, 0.54 [95% CI, 0.31-0.95]).

Conclusions: In this study, we found that the PPI user was not associated with risk of COVID-19 compared to H2RA users. There was no significant relationship between severe clinical outcomes of COVID-19 and exposure to PPI compared with H2RA, except for all-cause mortality.
Files in This Item:
T202200446.pdf Download
DOI
10.1186/s40360-022-00549-7
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
Yonsei Authors
You, Seng Chan(유승찬) ORCID logo https://orcid.org/0000-0002-5052-6399
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188072
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links